| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Bepirovirsen sodium targets all HBV messenger RNAs. As an antisense oligonucleotide, it binds to HBV mRNA transcripts through complementary base pairing, leading to their degradation or inhibition of translation. This results in reductions in HBV-derived RNAs, HBV DNA, and viral proteins. By targeting all HBV mRNAs, the compound achieves broad antiviral activity against hepatitis B virus.
|
|---|---|
| ln Vitro |
In vitro studies demonstrate that Bepirovirsen sodium is an antisense oligonucleotide that targets all HBV messenger RNAs. It leads to reductions in HBV-derived RNAs, HBV DNA, and viral proteins. The compound shows antiviral activity against hepatitis B virus in cell-based systems. Detailed in vitro activity data, including IC50 values and knockdown efficiency, are not extensively documented in the available literature.
|
| ln Vivo |
In vivo activity of Bepirovirsen sodium has been investigated in the context of chronic HBV infection. As an antisense oligonucleotide targeting all HBV mRNAs, it reduces HBV-derived RNAs, HBV DNA, and viral proteins in vivo. The compound has been studied in preclinical models and clinical trials for the treatment of chronic hepatitis B. Detailed in vivo data are available from the literature.
|
| Enzyme Assay |
The in vitro assay for Bepirovirsen sodium involves measuring its ability to reduce HBV RNA, HBV DNA, and viral protein levels. Cells infected with HBV are treated with the antisense oligonucleotide, and HBV RNA levels are measured by qPCR, HBV DNA by qPCR or Southern blot, and viral proteins by ELISA or Western blot. Standard protocols include appropriate controls such as scrambled oligonucleotides and vehicle controls.
|
| Cell Assay |
In vitro cell-based assays for Bepirovirsen sodium are conducted using HBV-infected cell lines such as HepG2.2.15 cells. Cells are treated with the compound at various concentrations, and HBV RNA, HBV DNA, and viral protein levels are measured. Cytotoxicity is evaluated using standard cell viability assays. Standard protocols include appropriate positive controls such as known anti-HBV agents and vehicle controls.
|
| Animal Protocol |
In vivo animal studies for Bepirovirsen sodium have been conducted using HBV transgenic mouse models or other HBV infection models. Animals are administered the compound via appropriate routes, and HBV RNA, HBV DNA, and viral protein levels in serum and liver tissues are measured. Pharmacokinetic parameters are determined from plasma samples. The compound has also been evaluated in clinical trials for chronic HBV infection.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Bepirovirsen sodium are typical of antisense oligonucleotides. As a nucleic acid-based compound, it is subject to degradation by nucleases in biological fluids. The compound has CAS number 2563929-84-8. Detailed pharmacokinetic parameters such as half-life, bioavailability, and tissue distribution are not extensively documented in the available literature. The compound is intended for research use only.
|
| Toxicity/Toxicokinetics |
Toxicity information for Bepirovirsen sodium is limited. As a research-use compound, standard safety precautions for handling should be followed. The compound is designated for research use only and is not for human therapeutic applications. No detailed toxicity data are available from the search results.
|
| References | |
| Additional Infomation |
Bepirovirsen sodium (ISIS 505358 sodium) is an antisense oligonucleotide targeting all HBV mRNAs. It leads to reductions in HBV-derived RNAs, HBV DNA, and viral proteins. It is used for research of chronic HBV infection. CAS 2563929-84-8. It is intended for research use only.
|
| Molecular Formula |
C230H290N88NA19O115P19S19
|
|---|---|
| Molecular Weight |
7762.00
|
| CAS # |
2563929-84-8
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Typically soluble in DMSO (e.g. 10 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.1288 mL | 0.6442 mL | 1.2883 mL | |
| 5 mM | 0.0258 mL | 0.1288 mL | 0.2577 mL | |
| 10 mM | 0.0129 mL | 0.0644 mL | 0.1288 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
